JP Morgan Chase
DRMA icon

JP Morgan Chase’s Dermata Therapeutics DRMA Stock Holding History

JP Morgan Chase’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-696
Closed -$1.61K – 7617
2025
Q4 		$1.61K Buy
+696
New +$2.27K ﹤0.01% 6975
2022
Q2 		– Hold
0
– -$1K – 6542
2022
Q1 		– Sell
-5
Closed -$17.1K – 6465
2021
Q4 		$21K Buy
+5
New +$44.2K ﹤0.01% 6197

Other funds holding DRMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase's DRMA Position: Q1 2026 in Review

JP Morgan Chase sold out of Dermata Therapeutics (DRMA) in Q1 2026, closing a stake of 696 shares — an estimated $1.61K sold.

JP Morgan Chase first reported a position in DRMA in Q4 2021 and held it in 2 quarters. The position peaked at $21K in Q4 2021. 7 funds tracked by Wall St. Rank hold DRMA as of Q1 2026.

  • JP Morgan Chase reported no remaining Dermata Therapeutics position as of Q1 2026 after selling out during the quarter.
  • JP Morgan Chase sold 696 Dermata Therapeutics shares in Q1 2026, an estimated $1.61K.
  • JP Morgan Chase first reported a position in Dermata Therapeutics in Q4 2021 and held it in 2 quarters.
  • JP Morgan Chase's Dermata Therapeutics position peaked at $21K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.